Journal of Biology and Medicine: Open Access
Combining Histone Deacetylase Inhibitors (HDACi) in a Specific Protocol Called Multi Targeted Epigenetic Therapy (MTET), Bruton's Tyrosine Kinase Inhibitors (BTKi), and Carbonic Anhydrase Inhibitors (CAi) in Cancer Treatment: Clinical Case Studies Highlighting Promising Results and Therapeutic Potential
M. Nezami MD, Steven Hager DO, Reza Shirazi MD, and Aryan Chaychian BS
Abstract
Carbonic anhydrase inhibitors (CAi), histone deacetylase inhibitors (HDACi), and Bruton’s tyrosine kinase inhibitors (BTKi) have demonstrated anticancer properties and the ability to target cancer stem cells. To the best of our knowledge, there is currently no existing in vivo or clinical literature investigating the exclusive combination of these three agents as a therapeutic approach for solid tumors. In this case series, we administered a combination of Acetazolamide, Tegretol, and Multi targeted epigenetic therapy (MTET protocol) consisting of quercetin, sodium phenyl butyrate, and Ibrutinib to end-stage patients with cancers of ovarian, colon, glioma, and sarcoma. Following treatment, a substantial reduction in tumor burden was consistently observed in all cases, as evidenced by labs –consisting of tumor markers and liquid biopsies (circulating tumor cells, and circulating DNA)– and imaging (whole body PET/CT). These findings collectively indicate that the combined use of HDACi, CAi, and BTKi as targeted epigenetic modifiers holds significant promise and clinical potential for improving the prognosis of patients with advanced-stage solid tumors across various cancer types.
Keywords: Multi targeted epigenetic therapy (MTET); Carbonic anhydrase inhibitors; Histone deacetylase inhibitors; Bruton's tyrosine kinase inhibitors; Epigenetic modifiers; Solid tumors; Cancer stem cells.
Journal Information
- Journal Name: Journal of Biology and Medicine: Open Access
- Journal Abbreviation: J Bio Med Open Access
- Journal Code: JBMOA
- Format of Publication: Online
- Frequency of Publication: Two Issue a Year
- Language: English
- Starting Year: 2020
- Subject: Biology, Medicine, Medical Sciences
- Review Process: Single-Blind Peer-Review by Referees
- Time to 1st Decision: 1 to 4 weeks from date of submission
- Time to Acceptance: 3 to 6 weeks, depending upon the required revision cycles
- Time to Publication: 1 to 2 weeks from date of final submission
- Editor-in-Chief: CHEE KONG YAP
Indexed and Abstracted In
